Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT00253539
First received: November 11, 2005
Last updated: April 11, 2011
Last verified: April 2011
  Purpose

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells. Hormone therapy using arzoxifene or tamoxifen may prevent breast cancer by lowering the amount of estrogen the body makes. The use of arzoxifene or tamoxifen may keep breast cancer from forming in women at high risk for breast cancer.

PURPOSE: This randomized phase II trial is studying arzoxifene to see how well it works compared to tamoxifen or a placebo in preventing breast cancer in premenopausal women at high risk for breast cancer.


Condition Intervention Phase
Breast Cancer
Hereditary Breast/Ovarian Cancer (brca1, brca2)
Drug: arzoxifene hydrochloride
Drug: tamoxifen citrate
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer

Resource links provided by NLM:


Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Ki67 in breast tissue of enrolled patients [ Time Frame: unknown ] [ Designated as safety issue: Yes ]
    The primary endpoint was changed in Ki67 in breast tissue of enrolled patients


Secondary Outcome Measures:
  • Toxicity [ Time Frame: unknown ] [ Designated as safety issue: Yes ]

Enrollment: 3
Study Start Date: January 2002
Study Completion Date: April 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
Drug: tamoxifen citrate
Given orally
Experimental: Arm II
Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
Drug: arzoxifene hydrochloride
Given orally
Placebo Comparator: Arm III
Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
Drug: arzoxifene hydrochloride
Given orally
Other: placebo
Given orally

Detailed Description:

OBJECTIVES:

  • Compare the effect of arzoxifene vs tamoxifen vs placebo on surrogate endpoints biomarkers, especially systemic insulin-like growth factor levels, in women at high risk for breast cancer.
  • Compare the toxic effects, biologic effects, clinical pharmacology, and pharmacodynamics of these drugs in these participants.
  • Determine the effect of these drugs on surrogate endpoint biomarkers in participants with BRCA1 and BRCA2 mutations.
  • Determine the feasibility of a chemoprevention study in participants with a strong family history of breast cancer.

OUTLINE: This is a randomized, placebo-controlled, double-blind study. Participants are randomized to 1 of 3 treatment arms.

  • Arm I: Participants receive oral tamoxifen once daily.
  • Arm II: Participants receive oral arzoxifene once daily.
  • Arm III: Participants receive an oral placebo once daily. In all arms, treatment continues for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment with their assigned study drug for an additional 6 months. Participants randomized to receive placebo are offered treatment with arzoxifene for an additional 6 months.

After completion of study treatment, participants are followed annually.

PROJECTED ACCRUAL: A total of 120 participants will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Estimated probability of carrying a BRCA1 or BRCA2 mutation ≥ 10% AND meets one of the following criteria:

    • Participants must have first-degree relatives (FDRs)* or second-degree relatives (SDRs)* (with an intervening male relative) with breast or ovarian cancer who satisfy one of the following criteria:

      • High-risk breast/ovarian cancer (non-Jewish families)

        • One FDR ≤ 40 years old** diagnosed with breast cancer
        • At least two FDRs or SDRs diagnosed with breast cancer at ≤ 50 years old OR had bilateral breast cancer
        • One FDR or one SDR diagnosed with breast cancer at ≤ 50 years old OR had bilateral breast cancer AND one FDR or SDR diagnosed with ovarian cancer
        • Three FDRs and/or SDRs diagnosed with breast or ovarian cancer (at least one in case of ovarian cancer)
        • Two FDRs and/or SDRs diagnosed with ovarian cancer
        • One male FDR or SDR diagnosed with breast cancer and one FDR or SDR (male or female) diagnosed with breast or ovarian cancer
      • Moderate-risk breast /ovarian cancer (non-Jewish families)

        • Two FDRs diagnosed with breast cancer with one ≤ 50 years old and/or both < 60 years old
        • One FDR and one SDR (mother or sister and maternal aunt or maternal grandmother) diagnosed with breast cancer if the sum of their ages is ≥ 118 years
        • One FDR and one SDR (mother or sister and paternal aunt or paternal grandmother) diagnosed with breast cancer if the sum of their ages is ≥ 78 years
        • Two SDRs (both maternal or both paternal) diagnosed with breast cancer if the sum of their ages is ≤ 98 years
        • One FDR with ovarian cancer
      • High-risk breast/ovarian cancer (Jewish families )

        • At least one FDR or SDR diagnosed with breast cancer at ≤ 50 years old
        • At least one FDR or SDR diagnosed with ovarian cancer
        • At least one FDR or SDR diagnosed with breast cancer at any age AND one FDR or SDR diagnosed with breast and/or ovarian cancer
        • At least one male FDR or SDR diagnosed with breast cancer NOTE: *FDRs are parents, siblings, and children of the participant; SDRs are aunts, uncles, grandparents, grandchildren, nieces, nephews, or half siblings of the participant

NOTE: **Age is approximated to the earliest age possible (e.g., a relative diagnosed in their 40's should be considered 40)

  • Patterns of cancer cases must all be on the maternal or paternal side of the family
  • Participants not meeting any of the above FDR or SDR criteria may provide medical documentation stating that they, a FDR, or a SDR carry BRCA1 or BRCA2 mutations

    • Participants with a prior history of breast cancer are eligible provided they have a remaining breast that has not been irradiated, all therapy for breast cancer was completed more than 2 years ago, and they are premenopausal
    • No ovarian cyst during screening
    • No more than 12 months since prior Pap smear with normal cytological results OR human papilloma virus negative if atypical squamous cells of uncertain significance (ASCUS) present
  • No higher degrees of atypia beyond ASCUS on Pap smear

    • No known history of osteoporosis (bone mineral density > 1.5 standard deviations below young adult norms)
    • Hormone receptor status
  • Not specified

PATIENT CHARACTERISTICS:

Menopausal status

  • Premenopausal, as defined by 1 of the following:

    • Last menstrual period < 6 months ago
    • Less than 45 years old AND underwent partial hysterectomy OR follicle-stimulating hormone within institutional pre-menopausal range within the past 3 months

Sex

  • Female

Performance status

  • ECOG 0-1

Life expectancy

  • More than 2 years

Hematopoietic

  • WBC ≥ 3,000/mm^3
  • Platelet count ≥ 125,000/mm^3
  • Hemoglobin ≥ 10 g/dL

Hepatic

  • Bilirubin ≤ 1.5 mg/dL
  • AST < 2 times upper limit of normal (ULN)
  • Albumin ≥ 3.0 g/dL
  • PT/PTT ≤ 1.25 times ULN

Renal

  • Creatinine ≤ 1.5 mg/dL OR
  • Creatinine clearance ≥ 60 mL/min

Cardiovascular

  • No history of deep venous thrombosis

Pulmonary

  • No history of pulmonary embolism

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile participants must use effective barrier-method contraception during and for 3 months after completion of study treatment
  • No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or cervical cancer ≤ stage I
  • No known addiction
  • Not undergoing treatment for an illicit drug addiction
  • Willing and able to undergo required study procedures (e.g., research-related breast biopsies)

PRIOR CONCURRENT THERAPY:

Chemotherapy

  • More than 2 years since prior chemotherapy

Endocrine Therapy

  • At least 3 months since prior oral contraceptives or intramuscular progestational agent
  • At least 3 months since prior luteinizing-hormone releasing hormone (LHRH) agonists or antagonists if agent was administered daily or monthly
  • At least 6 months since prior LHRH agonists or antagonists if agent was administered every 3 months
  • At least 6 months since prior antiestrogens (e.g., tamoxifen, toremifene, and raloxifene)
  • No concurrent progestational or contraceptive agents

Radiotherapy

  • See Disease Characteristics
  • More than 2 years since prior radiotherapy

Surgery

  • No prior prophylactic bilateral mastectomy

Other

  • No concurrent cholestyramine
  • No concurrent routine warfarin, bromocriptine, or phenobarbital
  • No other concurrent investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00253539

Sponsors and Collaborators
The Cleveland Clinic
Investigators
Study Chair: George T. Budd, MD The Cleveland Clinic
  More Information

Additional Information:
No publications provided

Responsible Party: G Thomas Budd, MD, Cleveland Clinic Foundation/Taussig Cancer Institute
ClinicalTrials.gov Identifier: NCT00253539     History of Changes
Other Study ID Numbers: CASE-CCF-4713, P30CA043703
Study First Received: November 11, 2005
Last Updated: April 11, 2011
Health Authority: United States: Federal Government

Keywords provided by The Cleveland Clinic:
hereditary breast/ovarian cancer (BRCA1, BRCA2)
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Ovarian Neoplasms
Adnexal Diseases
Breast Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Skin Diseases
Urogenital Neoplasms
Estrogen Receptor Modulators
Selective Estrogen Receptor Modulators
Tamoxifen
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014